Large Prospective Lung Cancer Study To Be Presented at ESMO Congress Shows Idylla™ Reduces EGFR Mutation Testing Turnaround Time by More than a Week, Allowing Faster Patient Management Decisions ...
Mechelen, Belgium, 9 February 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the launch of the ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for ...
Mechelen, Belgium, 23 October 2024 – Biocartis NV (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that six abstracts highlighting the benefits of Idylla™ will be ...
Biocartis Showcases Growing Impact of Idylla™ Platform at AMP 2025 Multiple abstracts and a corporate workshop highlight Idylla™’s growing role in oncology diagnostics Itasca, IL, United States, 14 ...
Researchers evaluated the use of the Idylla™ ctKRAS and ctEGFR Mutation Assays on cytology supernatants from lung cancer patients. The study demonstrated high concordance with next-generation ...
Biocartis and SkylineDx Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™ Mechelen, Belgium, 22 April 2021 - Biocartis Group NV (the ...
Six Idylla™ abstracts from renowned institutions will be presented at this year's AMP conference, showcasing the strong collaborations Biocartis has built with leading research and academic partners.
Evaluation of the Idylla™ GeneFusion Assay for First-Line Ultrarapid Detection of NTRK Fusions in Solid Tumor Samples (Gloria et al., 2025) Collaborative work between MD Anderson Cancer Center, Mayo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback